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Abstract
Objectives: Type 1 diabetes mellitus (T1DM) in children
often starts before the achievement of peak bone mass.
This may constitute a landmark in predicting bone frac-
ture risk later in their lives. This study aims to determine
the serum levels of bone markers in children with T1DM
in combination with their bone mineral density (BMD).
Methods: Children diagnosed with T1DM for 3 years or
more without signs of puberty were included in the diabetic
group.Another groupof age-matched healthy non-diabetic
controls was recruited from a local school. The serum levels
of a group of biochemical markers for bone formation and
resorption were determined in both study groups, and
BMD was measured by ultrasound absorptiometry.
Results: Thirty six children with T1DM and 39 normal
children were included in this study. The results showed
that 24/36 (66.7%) diabetic children had a Z score below
zero. Of these, five scored below 1. In contrast, 12/39
(30.8%) children from the control group had a Z score
below zero, but none had a score below 1. Significantly
lower levels of osteocalcin and procollagen N-terminal
peptide were detected in the diabetic group. The serum
levels of bone resorption markers were significantly
higher in the diabetic group.y. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2015.03.004
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mation and increases some bone resorption biomarkers.
BMD and bone markers are useful diagnostic tools for
the early detection of alterations in the bone quality of
children with T1DM. This, if treated in a timely manner,
may decrease future bone fracture susceptibility.
Keywords: Bone mineral density; Osteoporosis; Osteocalcin;
Quantitative ultrasound; Vitamin D
 2015 The Authors.
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Osteoporosis has become an alarming health problem
throughout the entire world, and approximately 200 million
people in the world are threatened by this deleterious dis-
ease.1,2 Osteoporosis is often described as a silent disease
because it is typically asymptomatic until a fracture
occurs.3 Like osteoporosis, diabetes mellitus (DM) is a
pandemic and a chronic metabolic disorder. In fact, 374
million people in the world may suffer from diabetic
complications.3e6 As a chronic condition, DM adversely
affects many different parts of the body including bones,
nerves, muscles, eyes, and kidneys.4 As increased rates of
bone fractures and osteoporosis have been found among
patients with type 1 DM (T1DM),5,7e11 in both
children12,13 and adults,14 and because the mechanisms of
diabetic effects on bone cells are very complex, several
researchers have described different mechanisms that
showed how DM induces osteoporosis and bone fractures
through multiple pathways.6,14,15
Bone marrow-derived endothelial progenitor cells (EPCs)
play a significant role in bone healing.5,16 DM was found to
down-regulate the expression of EPCs through different
mechanisms and thereby decrease bone formation at fracture
sites.5,17,18 DM is also responsible for the deposition of lipid
in the bone marrow, thereby leading to the expansion of the
marrow cavity and a decrease in the rate of blood flow to the
bone, which is required for the transfer of nutrients.5 The
transformation of osteoblast to adipocyte leads to the
reduction of osteoblasts available for bone formation.5,19 It
is known that DM is responsible for the over expression of
advanced glycation end products (AGE) and has roles in
bone rigidity.20,21 Pancreatic b cells also produce other
osteoporotic factors including amylin and preptin. Amylin
and preptin induce bone formation and sequester bone
resorption and reduce the apoptosis of osteoblasts.4
Osteocalcin is a peptide that positively regulates
osteogenesis. DM limits the production of osteocalcin
through the negative regulation of osteoblasts by decreased
synthesis of insulin, amylin and preptin.
Dual energy X-ray absorptiometry and peripheral quan-
titative computed tomography may be used to measure bone
mineral density (BMD) in children who are exposed to anincreased risk of osteoporosis in their adulthood, but both
expose children to unnecessarily ionizing radiation, which is
a limiting factor for preventive studies in children. Therefore,
in recent years, quantitative ultrasound (QUS) methods have
been developed to assess bone mineral status in some pe-
ripheral skeletal sites such as hand phalanges, tibia and
calcaneus. QUS techniques are safe, easy to use, radiation-
free, and come with portable devices so they are particu-
larly suitable and indicated to assess bone mineral status in
children.
The optimal use of bone marker measurement with
assessment of BMD using QUS of the calcaneum in pre-
dicting osteoporosis has not yet been established. Therefore,
the present study aims to investigate the levels of bone
markers in plasma of children with T1DM in combination
with their BMD.
Materials and Methods
Setting
This study was conducted in the Maternity and Children
Hospital (MCH), Almadinah Almunawwarah, Kingdom of
Saudi Arabia and was approved by the MCH research and
ethics committee. The diabetes unit at MCH provides
comprehensive services for children with DM up to the age of
12 years, and the city has one of the highest incidences of
childhood T1DM in the world.22
Inclusion and exclusion criteria
Patients diagnosed with T1DM for 3 years or more
without signs of puberty were included.We excluded patients
with a history of fractures of less than 1 year and those with
associated bone/joint problems, liver disease or patients on
long-term steroid therapy. Patients with incomplete data
were also excluded.
Control and diabetic groups
Informed written consent was obtained from all of the
families of the participating children. All 36 T1DM patients
were included from the Endocrine and Diabetes Unit, MCH,
from February to May 2013. 39 age-matched healthy non-
diabetic controls were recruited from a local school. The
study included 75 children (age 4e12 years), with 49 males
and 26 females. Biochemical markers for bone formation and
resorption and QUS for BMD were utilized for all patients
and the control group.
Measurement of bone mineral density (BMD)
BMD in the current study was measured using The Lunar
Achilles (InSight, GE Healthcare, USA), which is a proven
bone ultrasonometer to avoid exposing the children to un-
necessarily ionizing radiation. In this study, BMD was
measured using QUS of left calcaneum according to the
method of Valerio et al.23 All measurements were converted
to Z-scores using a data bank for age-matched speed of
sound values supplied by the manufacturer.
Figure 1: Bone mineral density (Z score) versus age for children
with type 1 diabetes mellitus compared to the non-diabetic control
group.
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Human osteocalcin assay was performed on a multiwell
plate.24 In addition, the levels of the bone formation markers
procollagen N-terminal peptide (PINP), and
carboxyterminalpropeptide of type I procollagen (PICP),
bone resorption markers [tartrate resistant acid
phosphatase (TRAP), pyridinoline (PYD), cross-linked car-
boxy-terminal telopeptide of type I collagen (CTX-I) and
deoxypridinoline (DPD)] and vitamin D were measured us-
ing appropriate commercial ELISA kits (MyBioSource
Incorporation, San Diego, CA, USA).
Assay of bone alkaline phosphatase activity
Alkaline phosphatase (ALP) (AlP; EC 3.1.3.1) catalyses
the transfer of the phosphate group from para-nitrophenyl
phosphate and liberating para-nitrophenol in an alkaline
medium. The incubation mixture contained 2-amino-2-
methyl-1-propanol (0.35 mol/L), zinc sulphate (1 mmol/L),
magnesium acetate (2 mmol/L), pH 10.4, 4-nitro-
phenylphosphate (12 mmol/L), and 20 microliters of plasma.
The liberated para-nitrophenol was measured calorimetri-
cally at 405 nm every minute for three minutes, and the
average absorbance per minute was calculated.25
Statistical analyses
Statistical analyses were performed using the SPSS sta-
tistical software package. Normality and homogeneity of the
data were confirmed before ANOVA; differences among the
study groups were assessed by one-way ANOVA followed by
Duncan’s multiple range tests.
Results
There is no significant difference between the mean age of
both groups of the control and diabetic children. As ex-
pected, all diabetic children showed higher levels of glycated
haemoglobin (HgA1C) than those of control group (Table 1).
Figure 1 shows the distribution of Z score versus age among
control and diabetic children. It shows that the majority of
diabetic children have Z scores below zero (24/36, 66.7%
with a mean Z score of 0.593  0.230), and five of them
(13.9%) actually have Z scores below 1 (low BMD),
whereas only 12/39 (30.8%) of the children in the control
group are below zero and no one was below 1 (mean ofTable 1: Characteristics of children with type 1 diabetes mel-
litus and control subjects.
Variables Non-diabetic
control
(n ¼ 39)
Group with
Type 1 diabetes
mellitus (n ¼ 36)
P value
BMD (Z score) 0.495  0.169 0.593  0.230 <0.05
Age (Years) 7.89 7.99 >0.05
Hg A1C Normal 10.69  0.392 <0.05
Duration of
diabetes (Years)
0.0 4.51  0.298 <0.05Z score 0.495  0.169), which indicates that diabetes
plays a role in decreasing BMD.
Among bone formation markers, osteocalcin and PINP
levels were significantly lower in diabetic children than in the
control subjects. Conversely, PICP did not differ signifi-
cantly (Table 2). Among bone resorption markers in diabetic
children, TRAP, PYD and CTX-1 levels were found to be
significantly higher in diabetics (Table 3). On the other hand,
the level of vitamin D (non-diabetic 23.94  0.98, diabetics
26.79  1.05) did not differ significantly (P > 0.05)
between the two groups, although the level in diabetic
children was slightly higher.
Discussion
Many studies have confirmed that T1DM is associated
with decreased BMD.26e28 In agreement with these
observations, the present study showed that BMD (Z
score) was lower in T1DM patients than in the control
group. The score in most children was not low enough to
be labelled as high risk for fractures at the time of the
study, which explains why they did not experience frequent
fractures. Conversely, 13.9% of the diabetic children had ZTable 2: Changes in bone formation markers in diabetic
children.
Biochemical
parameters
Non-diabetic
control
Diabetic
children
P value
Osteocalcin [ng/ml] 48.50  1.50 38.50  1.06 <0.001
PINP [ng/ml] 914.07  142.5 829.30  28.25 <0.05
Alkaline
Phosphatase
177.80  31.76 171.50  21.93 >0.05
PCIP [ng/ml] 33.00  0.47 34.96  3.86 >0.05
Table 3: Changes in bone resorption markers in diabetic
children.
Biochemical
parameters
Non-diabetic
control
Diabetic
children
P value
TRAP [ng/ml] 27.87  1.24 38.34  1.48 <0.05
DPD [ng/ml] 107.97  2.47 109.35  2.51 >0.05
PYD [ng/ml] 29.49  1.38 37.20  5 <0.05
CTX-1 [ng/ml] 48.18  1.67 54.73  5.68 <0.05
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a Z score below 1. This may explain the higher percentage
of osteopenia in older diabetics compared to the general
population. Keeping this in mind, one might suggest
interfering earlier in diabetic children to prevent future
osteopenia and osteoporosis with proper advice regarding
exercise and supplementations.
The development of biochemical markers that are specific
and sensitive in reflecting the overall rate of bone formation
and resorption has markedly improved the non-invasive
evaluation of bone turnover in various metabolic bone dis-
eases such as DM.29,30 Serum or plasma bone specific ALP
(BSAP), osteocalcin, P1CP and P1NP are the most widely
measured bone formation markers. The levels of
osteocalcin and P1NP in the present study were lower in
the serum of diabetic children than that of non-diabetic
control. Supporting our finding, it has been found that dia-
betic osteopenic patients displayed lower serum levels of
P1NP, which reflects poor bone formation.31 P1NP has
several functional advantages and has been recommended
by the one Marker Standards Working Group due to low
inter-individual variability32 and its stability in serum at
room temperature.33 It is also used as a preliminary
biomarker on the effectiveness of a given drug on bone
formation.
In the present study, the decreased level of osteocalcin was
correlated with low BMD, whereas the activity of ALP was
not. However, in other studies, BMDwas not correlated with
either osteocalcin or ALP.34,35 A decrease in bone formation
in DM might be due to low levels of serum PTH.36,37 In
addition, DM reduces osteocalcin levels through the
negative regulation of osteoblasts by decreased synthesis of
insulin, amylin and preptin.4
The majority of bone resorption markers are bone
collagen degradation products, with the exception of TRAP.
Examples include PYD and DPD, and CTX-1, of which
CTX-1 is considered the marker of choice.38 TRAP in
children with T1DM increased gradually and after 12
months was higher than at onset.38,39 In the current study,
the levels of TRAP, CTX-1 and PYD increased in the
serum of diabetic children compared to that of normal
children. In other studies, it has been found that levels of
both CTX-1 and BMD were lower in T1DM than in the
control group.39,40 It has been suggested that increased
inflammation and induced levels of cytokines are
responsible for the acceleration of bone turnover and bone
loss in DM patients.41 Another possible mechanism is that
DM is associated with oxidative reactions. Many studies
have shown that increases in free oxygen radical levels
could induce tissue damage and abnormalities in
antioxidant defences in DM.42,43 Oxidative stress canimpair the balance between proteolytic enzymes and their
inhibitors that may cause or worsen osteoporosis in DM
patients.44 In vitro studies have shown that oxidative stress
inhibits osteoblastic differentiation and induces osteoblast
insults and apoptosis. Thus, oxidative stress may be related
to the pathogenesis of bone disorders.43,45,46
We conclude that children with T1DM have lower BMD
(Z score), low bone formation and high bone resorption
markers, which might lead to osteoporosis in the future.
Future double-blind studies on the benefits of early inter-
vention to reduce the chances of osteoporosis in diabetics are
needed. Moreover, bone marker measurements in combina-
tion with BMD are more useful than measuring BMD alone
for predicting osteoporosis in diabetic children. In addition,
we recommend the QUS devices for their simplicity, the lack
of radiation exposure, and the ease of the examination,
which can be carried out at a bedside.
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